 |
|
|
| |
The Second-Generation Hepatitis B Virus (HBV) Core Inhibitor (CI) ABI-H2158
is Associated with Potent Antiviral Activity in a 14-Day Monotherapy Study
in HBeAg-positive Patients with Chronic Hepatitis B (CHB)
|
| |
| |
AASLD 2019 Nov 8-12 Boston
Reported by Jules Levin
Man-Fung Yuen1, Kosh Agarwal2, Ed Gane3, Tuan T. Nguyen4, Tarek I. Hassanein5, Dong Joon Kim6, Katia Alves7, Hany Zayed7, Dongmei Qiang7, Eric Ruby7, Marc Evanchik7, Qi Huang7, Steven J. Knox7, and Richard Colonno7 on behalf of the ABI-H2158 Study Team
1University of Hong Kong, Hong Kong; 2King's College Hospital Foundation Trust, London, United Kingdom; 3Auckland Clinical Studies Limited, Auckland, New Zealand; 4T. Nguyen Research and Education, San Diego, CA;
5Southern California Research Center, Coronado, CA; 6Hallym University Chuncheon Sacred Heart Hospital, Chuncheon, Republic of Korea; 7Assembly Biosciences, Inc., South San Francisco, CA
|
| |
|
|
|
|
|
